Nammalwar B R, Vijaykumar M, Prahlad N, Jain Dilipkumar V
Division of Nephrology, Kanchi Kamakoti CHILDS Trust Hospital, 12A, Nageswar Road, Nungambakkam, Chennai 600 034, Tamilnadu, India.
Indian Pediatr. 2006 Jan;43(1):39-43.
A prospective study was undertaken to find out the benefit of immunosuppressive therapy(IV methyl prednisolone followed by oral prednisolone therapy for one year along with six doses of pulse monthly IV cyclophosphamide) in children with steroid resistant nephrotic syndrome. Thirty-four children with steroid resistant nephrotic syndrome were treated with above regime. The remission of the disease was determined at the end of first, second and third year. The above protocol could induce and maintain remission in 81.8% of children with minimal change nephrotic syndrome, 66.7% of children with diffuse mesangial proliferation and in only 16.7% of children with focal segmental glomerulosclerosis at the end of three years of the study. The therapy of IV methyl prednisolone followed by oral prednisolone for one year with 6 monthly pulse IV cyclophosphamide, is beneficial in children with steroid resistant minimal change disease and diffuse mesangial proliferative glomerulonephritis. The therapy is not effective in focal segmental glomerulosclerosis.
开展了一项前瞻性研究，以探究免疫抑制疗法（静脉注射甲泼尼龙，随后口服泼尼松龙治疗一年，并每月静脉注射六剂环磷酰胺脉冲）对激素抵抗型肾病综合征患儿的益处。34名激素抵抗型肾病综合征患儿接受了上述治疗方案。在第一、第二和第三年末确定疾病缓解情况。在研究的三年末，上述方案可使81.8%的微小病变型肾病综合征患儿、66.7%的弥漫性系膜增生患儿以及仅16.7%的局灶节段性肾小球硬化患儿实现并维持缓解。静脉注射甲泼尼龙，随后口服泼尼松龙一年，并每月静脉注射六剂环磷酰胺脉冲的治疗方法，对激素抵抗型微小病变病和弥漫性系膜增生性肾小球肾炎患儿有益。该疗法对局灶节段性肾小球硬化无效。
